Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for ion channels.


 

Fig. 1. The screening workflow of Receptor.AI

It features detailed molecular simulations of the ion channel in its native membrane environment across its open, closed, and inactivated forms, coupled with ensemble virtual screening considering conformational mobility in these states. Potential binding sites are explored within the pore, in the gating region, and at allosteric locations to encompass all potential mechanisms of action.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P16389

UPID:
KCNA2_HUMAN

ALTERNATIVE NAMES:
NGK1; Voltage-gated K(+) channel HuKIV; Voltage-gated potassium channel HBK5; Voltage-gated potassium channel subunit Kv1.2

ALTERNATIVE UPACC:
P16389; A0A024R0D3; A8K1Z6; Q86XG6

BACKGROUND:
The protein KCNA2, also known as Voltage-gated potassium channel subunit Kv1.2, plays a critical role in regulating neuronal excitability and neurotransmitter release, including dopamine and GABA. It achieves this through forming potassium channels that respond to the electrochemical gradient, crucial for brain and cardiovascular system functions. Its modulation by cytoplasmic beta subunits and interaction with other KCNA family members highlight its complex regulatory mechanisms.

THERAPEUTIC SIGNIFICANCE:
Given KCNA2's involvement in Developmental and Epileptic Encephalopathy 32 and its presynaptic role in preventing hyperexcitability, targeting KCNA2 offers a promising avenue for therapeutic development. Enhancing our understanding of KCNA2 could open doors to potential therapeutic strategies for neurological conditions characterized by aberrant neuronal firing.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.